Sun Pharm Inds Inc patents expiration
1. Absorica patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7435427 | SUN PHARM INDS INC | Pharmaceutical semi-solid composition of isotretinoin |
Sep, 2021
(2 years ago) | |
| US9089534 | SUN PHARM INDS INC | Pharmaceutical semi-solid composition of isotretinoin |
Sep, 2021
(2 years ago) | |
| US8367102 | SUN PHARM INDS INC | Pharmaceutical semi-solid composition of isotretinoin |
Sep, 2021
(2 years ago) | |
| US9078925 | SUN PHARM INDS INC | Pharmaceutical semi-solid composition of isotretinoin |
Sep, 2021
(2 years ago) | |
| US8952064 | SUN PHARM INDS INC | Pharmaceutical semi-solid composition of isotretinoin |
Sep, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 25, 2015 |
Drugs and Companies using ISOTRETINOIN ingredient
Market Authorisation Date: 25 May, 2012
Treatment: Treatment of a skin disorder
Dosage: CAPSULE;ORAL
How can I launch a generic of ABSORICA before it's drug patent expiration?
More Information on Dosage
ABSORICA family patents
2. Ortikos patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10172802 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(12 years from now) | |
| US9707182 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(12 years from now) | |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 13 June, 2019
Treatment: Treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon
Dosage: CAPSULE, DELAYED RELEASE;ORAL
More Information on Dosage
ORTIKOS family patents
3. Sezaby patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857683 | SUN PHARM INDS INC | Stabilization of phenobarbital sodium for injection |
Apr, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-414) | Nov 17, 2029 |
Drugs and Companies using PHENOBARBITAL SODIUM ingredient
Market Authorisation Date: 17 November, 2022
Treatment: Method of treating neonatal seizures
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
SEZABY family patents